Literature DB >> 19826969

The natural history of drug-induced liver injury.

Einar Björnsson1.   

Abstract

The development of acute hepatocellular injury with jaundice in patients with drug-induced liver injury (DILI) has been associated with a case-fatality rate of 10 to 50%, depending on the drug involved. This observation, called "Hy's rule," is frequently used by regulatory agencies in assessing the hepatotoxic potential of drugs being tested in clinical trials. Registry studies from Sweden, Spain, and the United States have confirmed the validity of Hy's rule by demonstrating a 9 to 12% mortality rate in consecutive DILI patients. In patients with suspected DILI, the causative agent should be immediately discontinued, and hospitalized patients with severe coagulopathy or encephalopathy should be referred for potential liver transplantation. Recent studies have shown that DILI can infrequently evolve into chronic liver injury including cirrhosis and even liver-related morbidity and mortality in a minority of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19826969     DOI: 10.1055/s-0029-1240004

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  12 in total

Review 1.  Drug-induced liver injury: a clinical update.

Authors:  Marwan Ghabril; Naga Chalasani; Einar Björnsson
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

Review 2.  Nitric oxide in liver diseases.

Authors:  Yasuko Iwakiri; Moon Young Kim
Journal:  Trends Pharmacol Sci       Date:  2015-05-28       Impact factor: 14.819

3.  Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Authors:  Jean P Molleston; Robert J Fontana; M James Lopez; David E Kleiner; Jiezhun Gu; Naga Chalasani
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-08       Impact factor: 2.839

4.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.

Authors:  Anaïs Michaut; Dounia Le Guillou; Caroline Moreau; Simon Bucher; Mitchell R McGill; Sophie Martinais; Thomas Gicquel; Isabelle Morel; Marie-Anne Robin; Hartmut Jaeschke; Bernard Fromenty
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 5.  Pharmacogenomics of adverse drug reactions.

Authors:  Ann K Daly
Journal:  Genome Med       Date:  2013-01-29       Impact factor: 11.117

Review 6.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research.

Authors:  Joost Willebrords; Isabel Veloso Alves Pereira; Michaël Maes; Sara Crespo Yanguas; Isabelle Colle; Bert Van Den Bossche; Tereza Cristina Da Silva; Cláudia Pinto Marques Souza de Oliveira; Wellington Andraus; Venâncio Avancini Alves; Bruno Cogliati; Mathieu Vinken
Journal:  Prog Lipid Res       Date:  2015-06-11       Impact factor: 16.195

Review 7.  Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview.

Authors:  Divya Singh; William C Cho; Ghanshyam Upadhyay
Journal:  Front Physiol       Date:  2016-01-26       Impact factor: 4.566

8.  Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.

Authors:  Mathieu Porceddu; Nelly Buron; Célestin Roussel; Gilles Labbe; Bernard Fromenty; Annie Borgne-Sanchez
Journal:  Toxicol Sci       Date:  2012-10       Impact factor: 4.849

9.  Evaluation considerations for EHR-based phenotyping algorithms: A case study for drug-induced liver injury.

Authors:  Casey Lynnette Overby; Chunhua Weng; Krystl Haerian; Adler Perotte; Carol Friedman; George Hripcsak
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2013-03-18

10.  Modulatory potentials of aqueous leaf and unripe fruit extracts of Carica papaya Linn. (Caricaceae) against carbon tetrachloride and acetaminophen-induced hepatotoxicity in rats.

Authors:  Olufunsho Awodele; Omoniyi Yemitan; Peter Uduak Ise; Victor Olabowale Ikumawoyi
Journal:  J Intercult Ethnopharmacol       Date:  2016-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.